Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.80 |
| ▸ | DRD2 | P14416 | 5/20 | 0.78 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.78 |
| ▸ | HTR2A | P28223 | 6/20 | 0.62 |
| ▸ | HTR7 | P34969 | 4/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.61 |
| ▸ | DRD3 | P35462 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7722977 | 1.00 | ACHE (0.80) | ACHEDRD2SLC6A4HTR2AHTR7 | |
| Naphthalene SCHEMBL8523934 | 0.94 | ACHE (0.72) | ACHEDRD2SLC6A4HTR2AHTR7 | |
| SCHEMBL791116 | 0.93 | ACHE (0.77) | ACHEDRD2SLC6A4HTR2AHTR7 | |
| SCHEMBL1545611 | 0.92 | ACHE (0.93) | ACHEDRD2SLC6A4HTR2AHTR7 | |
| SCHEMBL791471 | 0.92 | ACHE (0.75) | ACHEDRD2SLC6A4HTR2AKCNH2 | |
| Hydrochloric Acid SCHEMBL1544617 | 0.92 | ACHE (0.75) | ACHEDRD2SLC6A4HTR2AHTR7 | |
| Hydrochloric Acid SCHEMBL1545291 | 0.91 | ACHE (0.73) | ACHEDRD2SLC6A4HTR2AKCNH2 | |
| Propylamine SCHEMBL28972666 | 0.91 | DRD2 (0.91) | ACHEDRD2SLC6A4HTR2AHTR7 | |
| SCHEMBL7351612 | 0.88 | ACHE (0.80) | ACHEDRD2SLC6A4HTR2AHTR7 | |
| SCHEMBL6182384 | 0.88 | ACHE (0.80) | ACHEDRD2SLC6A4HTR2AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078115-A1 | ALIPHATIC ACID AMIDE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2026-03-19 | — | — | US | disclosed |
| CN-114981264-B | Fatty acid amide derivatives | 住友制药株式会社 | 2024-07-26 | — | — | CN | disclosed |
| CN-114981264-A | Fatty acid amide derivatives | 住友制药株式会社 | 2022-08-30 | — | — | CN | disclosed |
| WO-2021132311-A1 | ALIPHATIC ACID AMIDE DERIVATIVE | 大日本住友製薬株式会社 | 2021-07-01 | — | — | WO | disclosed |
| US-9120767-B2 | Arylosulfonamides for the treatment of CNS diseases | ADAMED SP. Z.O.O. (PL) | 2015-09-01 | — | — | US | disclosed |
| US-20140336200-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | ADAMED SP. Z O.O. (PL) | 2014-11-13 | — | — | US | disclosed |
| US-8822517-B2 | Arylosulfonamides for the treatment of CNS diseases | ADAMED SP. Z O.O. (PL) | 2014-09-02 | — | — | US | disclosed |
| EP-2616440-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | Adamed sp. z o.o. (PL) | 2013-07-24 | — | — | EP | disclosed |
| US-20130172365-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | ADAMED SP. Z.O.O. (PL) | 2013-07-04 | — | — | US | disclosed |
| WO-2012035123-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | ADAMED SP. Z O.O. (PL) | 2012-03-22 | — | — | WO | disclosed |
| US-5552414-A | 1-(1H-indolyloxyalkyl)-4-(heteroaryl) piperidines and related compounds useful as antipsychotics and analgesics | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1996-09-03 | — | — | US | disclosed |
| US-5550130-A | ANTIPSYCHOTIC AGENTS, ANALGESICS | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1996-08-27 | — | — | US | disclosed |
| WO-1995011680-A1 | HETEROARYLPIPERIDINES, PYRROLIDINES AND PIPERAZINES AND THEIR USE AS ANTIPSYCHOTICS AND ANALGETICS | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1995-05-04 | — | — | WO | disclosed |
| US-5364866-A | Side effect reduction | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1994-11-15 | — | — | US | disclosed |
| EP-0612318-A1 | HETEROARYLPIPERIDINES, PYRROLIDINES AND PIPERAZINES AND THEIR USE AS ANTIPSYCHOTICS AND ANALGETICS | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1994-08-31 | — | — | EP | disclosed |
| EP-0377528-B1 | Piperidines, process for their preparation and pharmaceutical compounds containing them | LIPHA (FR) | 1993-12-08 | — | — | EP | disclosed |
| EP-0542136-A1 | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgetics | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1993-05-19 | — | — | EP | disclosed |
| WO-1993009102-A1 | HETEROARYLPIPERIDINES, PYRROLIDINES AND PIPERAZINES AND THEIR USE AS ANTIPSYCHOTICS AND ANALGETICS | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1993-05-13 | — | — | WO | disclosed |
| US-5001134-A | Piperidines, processes of preparation and medications containing them | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1991-03-19 | — | — | US | disclosed |
| EP-0377528-A1 | Piperidines, process for their preparation and pharmaceutical compounds containing them | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1990-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336200-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | ARSA, PMP22, STS | ACHE 815/4885DRD2 3216/4885SLC6A4 174/4885 |
| US-20130172365-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | ARSA, PMP22, STS | ACHE 815/4885DRD2 3216/4885SLC6A4 174/4885 |
| US-20260078115-A1 | ALIPHATIC ACID AMIDE DERIVATIVE | HTR1D, HTR1A, HTR7 | ACHE 2428/4885DRD2 28/4885SLC6A4 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.